2011
Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2‐positive breast cancer using an LC‐MALDI‐TOF/MS procedure
Mazouni C, Baggerly K, Hawke D, Tsavachidis S, André F, Buzdar A, Martin P, Kobayashi R, Pusztai L. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2‐positive breast cancer using an LC‐MALDI‐TOF/MS procedure. Proteomics Clinical Applications 2011, 5: 193-193. DOI: 10.1002/prca.201190010.Peer-Reviewed Original Research
2010
Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2‐positive breast cancer using an LC‐MALDI‐TOF/MS procedure
Mazouni C, Baggerly K, Hawke D, Tsavachidis S, André F, Buzdar AU, Martin P, Kobayashi R, Pusztai L. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2‐positive breast cancer using an LC‐MALDI‐TOF/MS procedure. Proteomics 2010, 10: 3525-3532. PMID: 20827732, DOI: 10.1002/pmic.201000057.Peer-Reviewed Original ResearchConceptsPreoperative chemotherapyBreast cancerHemopexin precursorHER2-positive breast cancerApolipoprotein APost-chemotherapy samplesPre-chemotherapy samplesPathological complete responseBreast cancer patientsNon-responding groupSerum amyloid PSerum protein levelsSerum protein profilesNeoadjuvant chemotherapyComplete responseResidual diseaseResponder groupCancer patientsTumor responseComplement 3Tumor markersAmyloid PChemotherapyPatientsProtein profiles